3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
7
Stomach Neoplasms
2
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neutropenia
1
Neoplasm Metastasis
1
Gastric and Gastroesophageal Junction Adenocarcinoma
1
Esophageal Squamous Cell Carcinoma
1
EFS
1
Colorectal Cancer Metastatic
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms
1
Anal Cancer Metastatic
1
Advanced Solid Tumors
1
Advanced Colorectal Cancer
1
Adenocarcinoma Of Esophagus
1
Adenocarcinoma
1
Interventions
durvalumab
18
Bevacizumab
17
atezolizumab
13
lenvatinib
10
Magnetic Resonance Spectroscopy
10
tremelimumab
8
Nivolumab
8
pembrolizumab
7
Sorafenib
6
Specimen Handling
5
camrelizumab
4
cabozantinib
4
Immunoglobulin G
4
Disulfides
4
sintilimab
3
apatinib
3
X-Rays
3
Radiotherapy
3
Radiofrequency Ablation
3
Radiation
3
Hepatectomy
3
E-7386
3
Doxorubicin
3
Cyclophosphamide
3
tislelizumab
2
relatlimab
2
dostarlimab
2
budigalimab
2
Standard of Care
2
Simvastatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Hepatocellular
×
trifluridine tipiracil drug combination
×
Clear all
NCT07138885
2026-04-29
DRIVE-II
Sun Yat-sen University
Phase 2
Active not recruiting
62 enrolled